NEW YORK, Feb. 27, 2026 /PRNewswire/ --  Average weekly trading volume of approximately 684,629 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 01/31/26 NAV 12.91 MKT 11.49 AVERAGE ANNUAL TOTAL RETURN AS OF 01/31/26 NAV (%) MKT (%) One-Month* 9.50 10.16 One-Year 25.47 26.00 Three-Year 15.65 15.76 Five-Year 9.87 10.58 10-Year 14.12 14.97 *Not Annualized Important Performance and Expense Information All ...

CLOSING PRICES AS OF 01/31/26NAV12.91MKT11.49AVERAGE ANNUAL TOTAL RETURN AS OF 01/31/26NAV (%)MKT (%)One-Month*9.5010.16One-Year25.4726.00Three-Year15.6515.76Five-Year9.8710.5810-Year14.1214.97*Not AnnualizedAll performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted. R ...

Core Insights - The article highlights the expertise of James Foord, an economist with a decade of experience in analyzing global markets, and his leadership role in The Pragmatic Investor, which focuses on building diversified investment portfolios [1] Group 1: Company Overview - The Pragmatic Investor aims to guide investors of all levels by providing insights into global macro trends, international equities, commodities, technology, and cryptocurrencies [1] - The platform offers various features including a dedicated portfolio, weekly market updates, actionable trades, technical analysis, and a chat room for discussions [1] Group 2: Market Focus - The investment group emphasizes the importance of creating robust portfolios that not only preserve but also increase wealth over time [1]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .There are several major investor concerns around the current market. One should be valuation levels, which are exceedingly stretched, viewed from a historical lens. Tariffs are another significant worry, given tariff policies are extrem ...

Key Takeaways NU stands out for scale, engagement and expanding lending across Latin America.FUTU drives high revenue per account, IPO strength and global expansion momentum.NU's faster 2026 growth estimates and broader ecosystem tip the balance in its favor.Both Nu Holdings (NU) and Futu Holdings Limited (FUTU) are prominent fintech players stirring up the market. NU, with its banking, credit cards and other financial services, serves the Latin American market. FUTU is a digital brokerage platform operatin ...

Key Takeaways Rocket Companies Q4 EPS of 11 cents beat estimates as revenues jumped 52% y/y.RKT posted $47.3B in closed loan originations and $41.6B in rate lock volume.Rocket Companies announced a three-year alliance with Compass to expand housing reach.Shares of Rocket Companies, Inc. (RKT) gained 8.1% in the after-market hours, following the release of its fourth-quarter and 2025 results. Adjusted earnings per share of 11 cents surpassed the Zacks Consensus Estimate by a penny. The bottom line grew signi ...

Key Takeaways CLOV posted a Q4 adjusted loss of 5 cents per share, in line with estimates, while revenues rose 44.7% y/y.Insurance revenues rose 46.9% on 38% Medicare Advantage membership growth and strong retention.CLOV raised the 2026 revenue view to $2.81-$2.92B and sees GAAP net income of $0-$20M.Clover Health Investments, Corp. (CLOV) delivered an adjusted fourth-quarter 2025 loss per share of 5 cents, against the year-ago period’s adjusted earnings per share (EPS) of 2 cents. The bottom line was in li ...

Key Takeaways UHS posted Q4 EPS of $5.88, missing estimates as admissions and patient days fell short.Universal Health saw 9% higher operating costs, driven by wages, supplies and expenses.UHS guided 2026 revenue of $18.417-$18.789B and EPS of $22.64-$24.52.Universal Health Services, Inc. (UHS) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $5.88, which missed the Zacks Consensus Estimate by 0.6%. The bottom line soared 19.5% year over year.Net revenues of $4.49 billion improved 9.1% year ...

Key Takeaways QBTS reports a Q4 loss of 12 cents, missing estimates, as revenues rise 19% y/y.D-Wave posts $13.4M in Q4 bookings, down 27%, but January bookings exceed $30M.QBTS ends 2025 with $884.5M cash after warrant exercises and the Advantage2 system launch.D-Wave Quantum Inc. (QBTS) reported a fourth-quarter 2025 net loss of 12 cents per share compared with the Zacks Consensus Estimate of a loss of 5 cents. However, the figure compares favorably with the year-ago period’s loss of 37 cents.Excluding on ...

Key Takeaways SOLV posted Q4 adjusted EPS of $1.57 on $1.99B revenue, topping consensus estimates.SOLV saw organic growth across MedSurg, Dental, and HIS, led by infection prevention and restoratives.SOLV's gross margin fell 270 bps, while adjusted operating income declined 5.9% year over year.Solventum (SOLV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which beat the Zacks Consensus Estimate of $1.50 by 4.7%. The bottom line improved 11.3% year over year.GAAP EPS in the quarter ...